*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Prompted by the need to refurbish their pipelines at lower costs and to drive and sustain future profits, drug companies have turned to drug repositioning, or repurposing, as a means of drug rediscovery. The process of drug repositioning identifies novel indications for clinical candidates that have been discontinued for their primary indications for reasons other than safety.
During this week’s podcast Dr. Andreas Persidis talks more about the motivations that lead drug companies to view repositioning as a viable business strategy. He discusses the key elements for achieving a successful drug repositioning program and provides specific examples of companies that have successfully repositioned their therapeutic products.
Dr. Persidis is president and co-founder of Biovista. He also served as svp at Upstate/Serologicals, managing director and president of RHeoGene, as well as assistant director, medical school technology transfer program, and assistant professor (adjunct) at the entrepreneurial center of the Wharton School of Business at the University of Pennsylvania (1993–1997). He also participated in co-founding Cellzome and Anadys.
Dr. Persidis was a recipient of the Honeywell European Futurist Award (1986) and has published extensively on biobusiness subjects. Between 1997 and 2000 he authored the monthly Industry Trends column for Nature Biotechnology. He has published more than 80 papers and book chapters, has lectured at Wharton, the Columbia Business School, George Washington University, and the University of Auckland Business School, and is a frequent speaker at major international meetings. Dr. Persidis holds a B.Sc. degree in biological chemistry from Essex University, U.K., and a Ph.D. in biochemistry from the University of Cambridge, U.K.